{"url_path":"/sec/cingw/8-k/2026-06-02/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1862150/0001493152-26-026760-index.html","accession_number":"0001493152-26-026760","cik":"0001862150","ticker":"CING","issuer_name":"Cingulate Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1862150/0001493152-26-026760-index.html","primary_entity_key":"0001862150","primary_entity_name":"Cingulate Inc."},"word_count":142,"has_tables":true,"body_markdown":"**Item\n7.01. Regulation FD Disclosure.**\n\n \n\nOn\nJune 2, 2026, Cingulate Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration\n(“FDA”) has issued a Complete Response Letter (“CRL”) for its New Drug Application for CTx-1301 (dexmethylphenidate\nHCl) for the treatment of Attention Deficit/Hyperactivity Disorder (“ADHD”). A copy\nof the press release is attached hereto as Exhibit 99.1.\n\n \n\nThe\ninformation included in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is not deemed to be “filed” for\npurposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall this Item\n7.01 and Exhibit 99.1 be incorporated by reference into the Company’s filings under the Securities Act of 1933, as amended, or\nthe Exchange Act, except as expressly set forth by specific reference in such future filing."}